Incyte to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time...

Incyte to Host Webcast and Conference Call on October 26, 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time

WILMINGTON, Del.--(Business Wire)--
Incyte Corporation (Nasdaq:INCY) announced today that it has
scheduled a webcast and conference call for 10:30 p.m. Eastern Time /
7:30 p.m. Pacific Time on Sunday, October 26, 2008 to discuss clinical
results from a Phase IIa trial of INCB18424, its oral JAK 1&2
inhibitor, in patients with rheumatoid arthritis. Results from the
Phase IIa trial will be presented at the 2008 American College of
Rheumatology (ACR) Annual Scientific Meeting that is being held in San
Francisco (details below):

-0-
*T
Presentation Title: A Randomized Placebo-Controlled Study of
INCB18424, a Selective Janus Kinase 1&2
(JAK1&2) Inhibitor in Rheumatoid Arthritis (RA)
Presenting Author: Larry Moreland
Session Name: RA Treatment: Small Molecules and Gene Therapy
Session Time: Sunday October 26, 2008 4:30 p.m. - 6:00 p.m.
Pacific Time
Presentation Time: 4:30 p.m. - 4:45 p.m. Pacific Time
Location: Hall B
Presentation Number: 714
*T

The schedules for the press release, webcast and conference call
are as follows:

-0-
*T
ACR Press Release: October 26, 2008 at 4:45 p.m. Pacific
Time / 7:45 p.m. Eastern Time

ACR Webcast & Conference Call: October 26, 2008 at 7:30 p.m. Pacific
Time / 10:30 p.m. Eastern Time
*T

The live webcast with slides from the presentation can be accessed
on Incyte's website:
http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-Calendar

Analysts and investors are also invited to participate in the
conference call by calling the following toll free numbers:

-0-
*T
Domestic Dial In Number: 877-407-8037
International Dial In Number: 201-689-8037
Conference ID #: 300810
*T

Please connect to Incyte's website prior to the start of the live
webcast to ensure adequate time for any software downloads that may be
necessary.

If you are unable to participate, a replay of the webcast will be
available on Incyte's website for 30 days and can be accessed at
www.incyte.com under Investor Relations, Events and Webcasts.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery
and development company focused on developing proprietary small
molecule drugs to treat serious unmet medical needs. Incyte's pipeline
includes multiple compounds in Phase I and Phase II development for
oncology, inflammation and diabetes. For additional information on
Incyte, visit the Company's web site at www.incyte.com.

Incyte Corporation
Pamela M. Murphy
Vice President, Investor Relations
& Corporate Communications
302-498-6944

Copyright Business Wire 2008